lobbying_activities: 1908230

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
1908230	a9b86c9c-f692-427a-8d4e-78cd1644f5cf	Q4	ADVANCED POLICY CONSULTING, LLC	401103524	AMGEN USA INC.	2016	fourth_quarter	HCR	Centers for Medicare & Medicaid Services (CMS) new coding regulation on biosimilar drug products. Opposition to the Center for Medicare and Medicaid Innovation's (CMMI) new Part B Drug model, which would put patient access and quality of care at risk.	HOUSE OF REPRESENTATIVES,SENATE	20000		0	0	2016-12-29T10:21:13.210000-05:00